Pathophysiological role of pigment epithelium-derived factor (PEDF) in hepatic disorders

Current Medicinal Chemistry

Volumn 17, Issue 19, 2010, Pages 1995-2000

  Yamagishi, S I ^a   Matsui, T ^a   Kawaguchi, T ^a,b   Sata, M ^a,b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Digestive Disease Information and Research ^*  (Japan)

Author keywords

Hepatic insulin resistance; Hepatocellular carcinoma; Oxidative stress; PEDF

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CANDESARTAN; INSULIN RECEPTOR SUBSTRATE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIGMENT EPITHELIUM DERIVED FACTOR; RAC1 PROTEIN; TELMISARTAN; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR;

ALCOHOL LIVER DISEASE; ANTIANGIOGENIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; DRUG MECHANISM; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; CARCINOMA, HEPATOCELLULAR; FATTY LIVER; LIVER DISEASES; LIVER NEOPLASMS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; PHYSIOLOGY;

CARCINOMA, HEPATOCELLULAR; EYE PROTEINS; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIVER DISEASES; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; OXIDATIVE STRESS; SERPINS;

EID: 77953481135     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791233670     Document Type: Article

References (66)

1. Teli, M.R.; James, O.F.; Burt, A,D.; Bennett, M.K.; Day, C.P. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology, 1995, 22, 1714-1719.
2. Dam-Larsen, S.; Franzmann, M.; Andersen, I.B.; Christoffersen, P.; Jensen, L.B.; Sørensen, T.I.; Becker, U.; Bendtsen, F. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut, 2004, 53, 750-755.
3. Matteoni, C.A.; Younossi, Z.M.; Gramlich, T.; Boparai, N.; Liu, Y.C.; McCullough, A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology, 1999, 116,1413-1419.
4. James, O.; Day, C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet, 1999, 353, 1634-1636.
5. Powell, E.E.; Cooksley, W.G.; Hanson, R.; Searle, J.; Halliday, J.W.; Powell, L.W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology, 1990, 11, 74-80.
6. Bellentani, S.; Saccoccio, G; Masutti, F.; Crocè, L.S.; Brandi, G.; Sasso, F.; Cristanini, G.; Tiribelli, C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med., 2000, 132, 112-117.
7. Chitturi, S.; Abeygunasekera, S.; Farrell, G.C.; Holmes-Walker, J.; Hui, J.M.; Fung, C.; Karim, R.; Lin, R.; Samarasinghe, D.; Liddle, C.; Weltman, M.; George, J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology, 2002, 35, 373-379.
8. Marchesini, G.; Brizi, M.; Bianchi, G.; Tomassetti, S.; Bugianesi, E.; Lenzi, M.; McCullough, A.J.; Natale, S.; Forlani, G.; Melchionda, N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 2001, 50, 1844-1850.
9. Hui, J.M.; Farrell, G.C. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them. J. Gastroenterol. Hepatol., 2003, 18, 1115-1117.
10. Marchesini, G.; Bugianesi, E.; Forlani, G.; Cerrelli, F.; Lenzi, M.; Manini, R.; Natale, S.; Vanni, E.; Villanova, N.; Mechlonda, N.; Rizzetto, M. Nonalcoholic fatty liver, steatohepatitis, and the meta-bolic syndrome. Hepatology, 2003, 37, 917-923.
11. Hyogo, H.; Yamagisghi, S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr. Pharm. Des., 2008, 14, 969-972.
12. Day, C.P.; James, O.F. Steatohepatitis: a tale of two hits? Gastroenterology, 1998, 114, 842-845.
13. Syn, W.K.: Teaberry, V.; Choi, S.S.; Diehl, A.M. Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis. Semin. Liver Dis., 2009, 29, 200-210.
14. Albano, E. New concepts in the pathogenesis of alcoholic liver disease. Expert Rev. Gastroenterol. Hepatol., 2008, 2, 749-759.
15. Liber, C.S. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol, 2004, 34, 9-19.
16. Tombran-Tink, J.; Chader, C.G.; Johnson, L.V. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp. Eye Res., 1991, 53, 411-414.
17. Tombran-Tink, J.; Barnstable, C.J. PEDF: a multifaceted neurotro-phic factor. Nat. Rev. Neurosci., 2003, 4, 628-636.
18. Dawson, D.W.; Volpert, O.V.; Gillis, P.; Crawford, S.E.; Xu, H.J.; Benedict, W.; Bouck, N.P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science, 1999, 285, 245-248.
19. Duh, E.J.; Yang, H.S.; Suzuma, I.; Miyagi, M.; Youngman, E.; Mori, K.; Katai, M.; Yan, L.; Suzuma, K.; West, K.; Davarya, S.; Tong, P.; Gehlbach, P.; Pearlman, J.; Crabb, J.W.; Aiello, L.P.; Campochiaro, P.A.; Zack, D.J. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest. Ophthalmol. Vis. Sci., 2002, 43, 821-829.
20. Spranger, J.; Osterhoff, M.; Reimann, M.; Mohlig, M.; Ristow, M.; Francis, M.K.; Cristofalo, V.; Hammes, H.P.; Smith, G.; Boulton, M.; Pfeiffer, A.F. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes, 2001, 50, 2641-2645.
21. Yamagishi, S.; Matsui, T.; Nakamura, K. Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiome-tabolic disorders. Curr. Pharm. Des., 2009, 15, 1027-1033.
22. Yamagishi, S.; Matsui, T.; Nakamura, K.; Ueda, S.; Noda, Y; Imai-zumi T. Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications. Curr.Drug Targets, 2008, 9, 1025-1029.
23. Rychli, K.; Huber, K.; Wojta, J. Pigment epithelium-derived factor (PEDF) as a therapeutic target in cardiovascular disease. Expert. Opin. Ther. Targets, 2009, 13, 1295-1302.
24. Wang, J.J.; Zhang, S.X.; Mott, R.; Chen, Y.; Knapp, R.R.; Cao, W.; Ma, J.X. Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am. J. Physiol. Renal. Physiol., 2008, 294, F1166-F1173.
25. Zhang, S.X.; Wang, J.J.; Gao, G.; Shao, C.; Mott, R.; Ma, J.X. Pigment epithelium-derived factor (PEDF) is an endogenous antiin-flammatory factor. FASEB J., 2006, 20, 323-325.
26. Zamiri, P.; Masli, S.; Streilein, J.W.; Taylor, A.W. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest. Ophthalmol. Vis. Sci., 2006, 47, 3912-3918.
27. Yamagishi, S.; Inagaki, Y.; Nakamura, K.; Abe, R.; Shimizu, T.; Yoshimura, A.; Imaizumi, T. Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J. Mol. Cell. Cardiol., 2004, 37, 497-506.
28. Yamagishi, S.; Nakamura, K.; Ueda, S.; Kato, S.; Imaizumi, T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res., 2005, 320, 437-445.
29. Yamagishi, S.; Matsui, T.; Nakamura, K.; Inagaki, Y.; Takenaka, K.; Jinnouchi, Y.; Yoshida, Y.; Matsuura, T.; Narama, I.; Motomiya, Y.; Takeuchi, M.; Inoue, H.; Yoshimura, A.; Bucala, R.; Imaizumi, T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J. Biol. Chem., 2006, 281, 20213-20220.
30. Inagaki, Y.; Yamagishi, S.; Okamoto, T.; Takeuchi, M.; Amano, S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia, 2003, 46, 284-287.
31. Yamagishi, S.; Ueda, S.; Matsui, T.; Nakamura, K.; Imaizumi, T.; Takeuchi, M.; Okuda, S. Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept. Lett., 2007, 14, 832-835.
32. Yamagishi, S.; Matsui, T.; Nakamura, K.; Yoshida, T.; Takeuchi, M.; Imaizumi, T. Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro. Horm. Metab. Res., 2007, 239, 233-235.
33. Yamagishi, S.; Matsui, T.; Nakamura, K.; Imaizumi, T. Pigment epithelium-derived factor (PEDF) inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties. Protein Pept. Lett., 2007, 14, 615-617.
34. Yamagishi, S.; Matsui, T.; Nakamura, K.; Yoshida, T.; Shimizu, K.; Takegami, Y.; Shimizu, T.; Inoue, H.; Imaizumi, T. Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Microvasc. Res., 2006, 2006, 71, 222-226.
35. Yamagishi, S.; Kikuchi, S.; Nakamura, K.; Matsui, T.; Takeuchi, M.; Inoue, H. Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2. Med. Chem., 2006, 2, 265-269.
36. Yamagishi, S.; Matsui, T.; Takenaka, K.; Nakamura, K.; Takeuchi, M.; Inoue, H. Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs). Diabetes Metab. Res. Rev., 2009, 25, 266-271.
37. Nakamura, K.; Yamagishi, S.; Matsui, T.; Yoshida, T.; Takenaka, K.; Jinnouchi, Y.; Yoshida, Y.; Ueda, S.; Adachi, H.; Imaizumi, T. Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am. J. Pathol., 2007, 170, 2159-2170.
38. Yoshida, Y.; Yamagishi, S.; Matsui, T.; Jinnouchi, Y.; Fukami, K.; Imaizumi, T.; Yamakawa, R. Protective role of pigment epithe-lium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab. Res. Rev., 2009, 25, 678-686.
39. Yamagishi, S.; Matsui, T.; Nakamura, K.; Takeuchi, M.; Imaizumi, T. Microvasc. Res., 2006, 72, 86.
40. Fujimura, T.; Yamagishi, S.; Ueda, S.; Fukami, K.; Shibata, R.; Matsumoto, Y.; Kaida, Y.; Hayashida, A.; Koike, K.; Matsui, T.; Nakamura, K.; Okuda, S. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Nephrol. Dial. Transplant., 2009, 24, 1397-1406.
41. Takenaka, K.; Yamagishi, S.; Matsui, T.; Nakamura, K.; Jinnouchi, Y.; Yoshida, Y.; Ueda, S.; Katsuki, Y.; Katsuda, Y.; Imaizumi, T. Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: a possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes. Atherosclerosis, 2008, 197, 25-33.
42. Yamagishi, S.; Imaizumi, T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.Curr. Pharm. Des. 2005, 11, 2279-2299.
43. Yamagishi, S.; Matsui, T.; Nakamura, K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr. Drug. Targets, 2007, 8, 1138-1143.
44. Yamagishi, S.; Ueda, S.; Matsui, T.; Nakamura, K.; Fukami, K.; Okuda, S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert. Opin. Investig. Drugs, 2008, 17, 983-996.
45. Unoki, H.; Yamagishi, S. Advanced glycation end products and insulin resistance.Curr. Pharm. Des., 2008, 14, 987-989.
46. Yoshida, T.; Yamagishi, S.; Nakamura, K.; Matsui, T.; Imaizumi, T.; Takeuchi, M.; Koga, H.; Ueno, T.; Sata, M. Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation. Horm. Metab. Res., 2008, 40, 620-625.
47. Yoshida, T.; Yamagishi, S.; Matsui, T.; Nakamura, K.; Takeuchi, M.; Ueno, T.; Sata, M. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation. J. Int. Med. Res., 2008, 36, 237-243.
48. Ho, T.C.; Yang, Y.C.; Chen, S.L.; Kuo, P.C.; Sytwu, H.K.; Cheng, H.C.; Tsao, Y.P. Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the perox-isome proliferator-activated receptor gamma. Mol. Immunol., 2008, 45, 898-909.
49. Yoshida, T.; Yamagishi, S.; Nakamura, K.; Matsui, T.; Imaizumi, T.; Takeuchi, M.; Ueno, T.; Sata, M. Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett., 2006, 580, 2788-2796.
50. Yoshida, T.; Yamagishi, S.; Nakamura, K.; Matsui, T.; Imaizumi, T.; Inoue, H.; Ueno, T.; Sata, M. Pigment epithelium-derived factor (PEDF) blocks the interleukin-6 signaling to C-reactive protein expression in Hep3B cells by suppressing Rac-1 activation. Life Sci., 2006, 79, 1981-1987.
51. Meshkani, R.; Adeli, K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin. Biochem., 2009, 42, 1331-1346.
52. Kerner, A.; Avizohar, O.; Sella, R.; Bartha, P.; Zinder, O.; Markiewicz, W.; Levy, Y.; Brook, G.J.; Aronson, D. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 193-197.
53. Crowe, S.; Wu, L.E.; Economou, C.; Turpin, S.M.; Matzaris, M.; Hoehn, K.L.; Hevener, A.L.; James, D.E.; Duh, E.J.; Watt, M.J. Pigment epithelium-derived factor contributes to insulin resistance in obesity. Cell Metab., 2009, 10, 40-47.
54. Notari, L.; Baladron, V.; Aroca-Aguilar, J.D.; Balko, N.; Heredia, R.; Meyer, C.; Notario, P.M.; Saravanamuthu, S.; Nueda, M.L.; Sanchez-Sanchez, F.; Escribano, J.; Laborda, J.; Becerra, S.P. Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J. Biol. Chem., 2006, 281, 38022-38037.
55. Chung, C.; Doll, J.A.; Gattu, A.K.; Shugrue, C.; Cornwell, M.; Fitchev, P.; Crawford, S.E. Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). J. Hepatol., 2008, 48, 471-478.
56. Chung, C.; Shugrue, C; Nagar, A; Doll, J.A.; Cornwell, M.; Gattu, A; Kolodecik, T.; Pandol, S.J.; Gorelick, F. Ethanol exposure depletes hepatic pigment epithelium-derived factor, a novel lipid regulator. Gastroenterology, 2009, 136, 331-340.
57. Wu, X.Z. New strategy of antiangiogenic therapy for hepatocellular carcinoma. Neoplasma, 2008, 55, 472-481.
58. Pang, R.; Poon, R.T. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett., 2006, 242, 151-167.
59. Matsumoto, K.; Ishikawa, H.; Nishimura, D.; Hamasaki, K.; Nakao, K.; Eguchi, K. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology, 2004, 40, 252-259.
60. Uehara, H.; Miyamoto, M.; Kato, K.; Ebihara, Y.; Kaneko, H.; Hashimoto, H.; Murakami, Y.; Hase, R.; Takahashi, R.; Mega, S.; Shichinohe, T.; Kawarada, Y.; Itoh, T.; Okushiba, S.; Kondo, S.; Katoh, H. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res., 2004, 64, 3533-3537.
61. Browne, M.; Stellmach, V.; Cornwell, M.; Chung, C.; Doll, J.A.; Lee, E.J.; Jameson, J.L.; Reynolds, M.; Superina, R.A.; Abramson, L.P.; Crawford, S.E. Gene transfer of pigment epithelium-derived factor suppresses tumor growth and angiogenesis in a hepatoblas-toma xenograft model. Pediatr Res, 2006, 60, 282-287.
62. Chung, C.; Doll, J.A.; Stellmach, V.M.; Gonzales, J.; Surapureddi, S.; Cornwell, M.; Reddy, J.K.; Crawford, S.E. Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha. Adv. Exp. Med. Biol., 2008, 617, 591-597.
63. Kawaguchi, T.; Yamagishi, S.I.; Itou, M.; Okuda, K.; Sumie, S.; Kuromatsu, R.; Sakata, M; Abe, M; Taniguchi, E.; Koga, H.; Harada, M.; Ueno, T.; Sata, M. Pigment epithelium-derived factor inhibits lysosomal degradation of Bcl-xL and apoptosis in HepG2 cells. AM. J. Pathology, 2009, 176, 168-176.
64. Yamagishi, S.; Adachi, H.; Abe, A.; Yashiro, T.; Enomoto, M.; Furuki, K.; Hino, A.; Jinnouchi, Y.;, Takenaka, K.; Matsui, T.; Nakamura, K; Imaizumi, T. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J. Clin. Endocrinol. Metab. 2006, 91, 2447-2450.
65. Nakamura, K.; Yamagishi, S.; Yoshida, T.; Matsui, T.; Imaizumi, T.; Inoue, H.; Sata, M. Hydrogen peroxide stimulates pigment epithelium-derived factor gene and protein expression in the human hepatocyte cell line OUMS-29. J. Int. Med. Res. 2007, 35, 427-432.
66. Yamagishi, S.; Matsui, T.; Adachi, H.; Takeuchi, M. Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. Pharmacol. Res., 2010, 61, 103-107.